排名前五的靶点	数量

IgE(免疫球蛋白E)	2
H3 receptor(组胺H3受体)	1
RARβ2(维甲酸受体β)	1
RELA(RELA proto-oncogene, NF-kB subunit)	1
ABCA4(ATP binding cassette subfamily A member 4)	1

关联

项与 King's College London 相关的药物

LEU-001

靶点

EGFR

作用机制

EGFR拮抗剂

在研机构

原研机构

在研适应症

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

IRL-201805

靶点

RANK x RANKL

作用机制

RANK抑制剂 [+2]

在研机构

Revolo Biotherapeutics Ltd. [+3]

原研机构

Peptinnovate Ltd [+1]

在研适应症

类风湿关节炎 [+3]

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

Rasolvir(King's College London)

靶点-

作用机制

免疫刺激剂

在研机构

King's College London

原研机构

King's College London

在研适应症

类风湿关节炎

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

1,230

项与 King's College London 相关的临床试验

NCT07004920

/ Not yet recruitingN/A

Adaptation and Validation of a Patient-centered Outcome Scale for People in the Intensive Care Unit (IPOS-ICU)

The focus of intensive care is on survival and the prolongation of life. The care of organ systems takes priority and is assessed through screening tools such as the Sequential Organ Failure Assessment (SOFA) score, which evaluates clinical and laboratory factors associated with prognosis. Despite advancements in modern intensive care, the hospital mortality rate for mechanically ventilated patients in 2022 was approximately 43%. Even for survivors of intensive care, post-intensive care syndrome poses a significant burden on quality of life.
Although intensive care and palliative care often appear to be contradictory, clinical overlap between these populations is common, with both experiencing physical, psychosocial, and spiritual challenges that frequently require input from specialized teams. Nevertheless, palliative care remains underrepresented in German intensive care units (ICUs), with only 1.4% of ICU patients on prolonged mechanical ventilation receiving specialist palliative care. Therefore, the identification of patients in need of palliative care and the reduction of barriers such as limited resources and varying clinician attitudes must be addressed. This necessitates a robust tool for measuring and assessing palliative care needs specifically in ICU patients, enabling the implementation of interventions aimed at minimizing the burden on patients, families, and treating clinicians, as well as guiding appropriate allocation of healthcare resources.
The Integrated Palliative Care Outcome Scale (IPOS) questionnaire was developed as a patient-centered measurement instrument from a palliative care perspective. IPOS enables the assessment of symptoms and needs from the viewpoint of patients and their families. For patients with COVID-19, an adapted version-IPOS-COV-was developed, wherein healthcare personnel assess patient symptoms and needs. However, no existing instrument comprehensively captures the physical, psychosocial, and spiritual needs of ICU patients and their families from a palliative care perspective. Such a tool could facilitate both the identification of patients requiring palliative care and serve as an endpoint for evaluating the effectiveness of palliative care interventions in ICU settings, including post-discharge outcomes related to post-intensive care syndrome affecting both patients and families.
The underlying hypothesis is that a patient-centered measurement instrument addressing physical, psychosocial, and spiritual needs from a palliative care perspective for ICU patients can be developed and validated based on the IPOS. Additionally, demographic data, clinical course, ICU interventions (e.g., mechanical ventilation, dialysis, palliative care consultations, family discussions, and therapy goal limitations), as well as SOFA scores and Palliative Phase of Illness (PPoI) classifications at the time of IPOS-ICU assessment, will be collected. It is hypothesized that IPOS-ICU scores will correlate with disease severity (as measured by SOFA and PPoI) and poor ICU outcomes, including length of stay, mortality, and discharge location. Furthermore, it is hypothesized that interventions such as palliative care consultations will be associated with lower IPOS-ICU scores. In the first phase of the study, an international and multiprofessional expert panel with experience in both intensive and palliative care will adapt the IPOS questionnaire for ICU patients, resulting in the development of the IPOS-ICU. The following modification strategies will be applied: rewording, removal, addition of items, adjustment of recall periods, and inclusion of a "cannot assess" response option. Online meetings will be conducted with representatives from Germany, Switzerland, the United Kingdom, the Czech Republic, and the United States. A larger review team will then evaluate the adapted version, and an informal "comfort consultation" will be conducted in ICU settings to ensure that the IPOS-ICU is considered appropriate and acceptable by ICU staff. Following adaptation, the validation phase will be conducted using a multicenter design. After obtaining informed consent from study participants, the IPOS-ICU will be administered at designated time points identified during the adaptation process. ICU staff (including at least one nursing professional and one medical professional) will complete the IPOS-ICU. The questionnaire will include an assessment of the PPoI (categorized as stable, unstable, deteriorating, dying, or deceased), and a free-text field for recording the estimated number of hours spent with the patient. Electronic Case Report Forms will capture demographic data, SOFA scores, treatment details, and outcomes following ICU discharge, all extracted from medical records. This study holds significant relevance by addressing the gap between the identification of palliative care needs and the actual implementation and evaluation of palliative care in ICU settings.

开始日期2025-11-01

申办/合作机构

Heinrich-Heine-Universität Düsseldorf

[+2]

NCT07115823

/ Not yet recruitingN/A

A Longitudinal, Cohort Study Investigating the Impact of General Anaesthetic Caesarean Birth, With or Without ICU Admission, on Maternal Mental Health and Mother/Infant Bonding

In the UK, approximately 6000 women every year undergo caesarean sections with general anaesthetic. Additionally, around 1300 women are admitted to Intensive Care Units (ICU) annually, typically due to pregnancy or childbirth complications. Some of these women are admitted to ICU for critical care immediately following a general anaesthetic caesarean section. However, there is little research on the impact of these experiences on women/birthing people and their families.
This project aims to explore the impact of general anaesthetic caesarean section, with or without subsequent ICU admission, on a mother's mental health and bonding with her newborn. Women and birthing people who have undergone a caesarean section with an epidural or spinal anaesthesia can also take part in this study, so that outcomes can be compared for different types of caesarean birth.

开始日期2025-11-01

申办/合作机构

King's College London

[+2]

NCT06992531

/ Not yet recruitingN/A

Auto-immune Contribution in Symptom-based Sensory and Autonomic Disorders

Postural Orthostatic Tachycardia Syndrome (PoTS) is a condition where the heart rate increases when standing up, causing symptoms like dizziness and fainting. It primarily affects young women and can be very disabling, impacting daily life. In addition to the typical symptoms related to standing, people with PoTS also experience unexplained pain and fatigue, which worsen their quality of life. The exact causes of PoTS are still unknown, but it is often triggered by viral infections and some PoTS patients show signs of immune system involvement, such as the presence of certain autoantibodies and other autoimmune conditions. Research on other chronic pain disorders, including fibromyalgia syndrome (FMS), has found that autoantibodies can cause pain by affecting how the nerves work. This study aims to investigate if similar immune-related mechanisms are behind the widespread pain seen in PoTS. This study will also look at how PoTS affects the nervous system by testing nerve activity in participants and assessing the number of nerve fibres in the skin, to check if similar changes can be seen in mice. This study will also involve participants with fibromyalgia syndrome and healthy volunteers.

开始日期2025-10-01

申办/合作机构

King's College London

[+2]

100 项与 King's College London 相关的临床结果

登录后查看更多信息

0 项与 King's College London 相关的专利（医药）

登录后查看更多信息

81,437

项与 King's College London 相关的文献（医药）

2026-01-01·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Optimizing super-feature selection for machine learning-enhanced spectroscopic analysis in biomedical research

Article

作者: Zhong, Jizhou ; Chan, Ka Lung Andrew ; Elsheikha, Hany M

PURPOSE:

Machine-learning-powered label-free infrared spectroscopic methods offer significant potential for diagnostic and biomedical applications. However, their applications have been limited by spectral noise, where critical features are often obscured by overlapping bands and data redundancy. Although various feature selection methods have been proposed, many suffer from limitations in consistency and interpretability. To address these challenges, we introduce a novel multi-model machine learning approach that integrates five distinct algorithms to identify a set of "super-features"-spectral features consistently deemed significant across all models.

PRINCIPAL RESULTS:

This novel workflow outperforms traditional algorithms, achieving superior classification accuracy (>99%) in distinguishing infected from healthy cells, despite using fewer spectral features. To ensure robustness and generalizability, we developed a comprehensive validation strategy that includes independent classifier evaluations, label randomization, and unsupervised analyses. Importantly, the identified super-features accurately differentiated infection states across multiple time points and enhanced the biological interpretability of infection-associated biochemical changes.

CONCLUSIONS:

These findings highlight the potential of advanced multi-model feature selection techniques to enhance the diagnostic power of spectroscopic data in biomedical research, offering high accuracy and valuable biological insights into infection progression.

2026-01-01·APPETITE

Parental use of distraction and portioning to reduce snack intake by children with avid eating behaviour: An experimental laboratory study

Article

作者: Farrow, Claire ; Haycraft, Emma ; Pickard, Abigail ; Croker, Helen ; Blissett, Jacqueline ; Edwards, Katie L ; Herle, Moritz ; Llewellyn, Clare

INTRODUCTION:

Children's avid eating behaviour is characterised by frequent snacking and food responsiveness. Parents need evidence-based advice on specific feeding practices, such as distraction techniques and portioning, that can be used to reduce children's intake of high energy-dense snacks. This experimental laboratory study tested the effectiveness of these feeding practices.

METHODS:

Parents and children (3-5 years; N = 129) who were identified as having an avid or typical eating profile were recruited and randomly allocated to one of three conditions. Following a standardised meal, children's energy intake (kcal) in the absence of hunger was assessed. While children had access to a snack buffet, parents were asked to use one of the following feeding practices: (1) Distract - using distraction techniques to delay children's snack intake; (2) Portion - allowing children to have snacks from pre-portioned pots; or (3) Control - allowing children to eat the type and number of snacks that their child wanted to.

RESULTS:

Children in the distraction condition consumed significantly less energy from snacks (M = 54.44 kcal, SD = 73.30) compared to children in the portion (M = 103.89 kcal, SD = 91.33, p < .001) or control condition (M = 115.92 kcal, SD = 90.55, p < .001). Energy intake in the portion and control conditions was not significantly different (p > .05). Children with avid versus typical eating profiles did not differ significantly in energy intake (p > .05).

CONCLUSION:

Parental use of distraction techniques may be effective for reducing children's intake of high energy-dense snacks and could be recommended for use to support the development of children's healthy eating. Research to examine the effectiveness of distraction in real-world settings is now needed.

2026-01-01·APPETITE

A qualitative exploration of women's experiences of food insecurity around pregnancy aligned with the socio-ecological model

Article

作者: Hdrc, Lambeth ; Bell, Z ; Davies, L ; Harding, S ; Marshall, J ; Lavelle, F ; Flynn, A C ; O'Leary, N

Pregnancy, postpartum, and infancy are pivotal periods when food insecurity (FI), defined as inconsistent access to sufficient, safe, and nutritious food, can adversely impact maternal and child health. Despite high FI rates in the UK, little is known about women's experiences during this time. This study explores FI during pregnancy and postpartum amongst a multi-ethnic group of women. Between October 2023 and February 2024 semi-structured interviews were conducted with purposively sampled food-insecure individuals (>18 years, pregnant or postpartum <12 months, residing in South London with recourse to public funds). Demographics were analysed with SPSS, and interviews using Reflexive Thematic Analysis in NVivo. Findings were discussed in alignment with the socio-ecological model. Three key themes were generated from eleven interviews. 1) Societal systems failure and its nutritional impact, 2) System 'soothers' mitigating FI, and 3) Creating Coordinated Care. Theme one describes the structural drivers' influencing maternal food strategies, eating and feeding behaviours. Theme two explores factors protecting or inhibiting women access to support. Theme three discusses the benefits and opportunities for improved health and social care coordination to address FI during pregnancy. This study emphasizes how structural determinants exacerbate FI during pregnancy and postpartum, with unique structural drivers to this life course period worsening its impact. FI influences health eating despite resourceful cooking and food management strategies. Greater coordinated care is urgently needed to address FI, promote healthy diets, and improve access.

269

项与 King's College London 相关的新闻（医药）

2025-09-07

·ioncology

新加坡ACTRIS首席医疗官Francesca Lorraine Wei Inng Lim教授分享新加坡细胞治疗全景

点击蓝字关注我们 2025年8月22日至23日，由中国北京健康促进会与广州市红棉肿瘤和罕见病公益基金会联合主办、北京陆道培血液病研究院承办的第十三届陆道培血液病学术大会在京隆重召开。本次会议汇集全球顶尖血液学专家，聚焦造血干细胞移植、细胞治疗、血液肿瘤精准诊疗等核心议题，为千余名参会者呈现了一场高规格、深层次的学术盛宴。会议期间，新加坡总医院Francesca Lorraine Wei Inng Lim教授分享了“新加坡细胞治疗全景（Cell Therapy Landscape in Singapore）”的精彩报告。《肿瘤瞭望-血液时讯》特邀Francesca Lorraine Wei Inng Lim教授围绕核心问题展开深入对话，以期为优化细胞治疗领域提供重要的实践指导与理论参考。 PART.1 新加坡近年在细胞与基因治疗（CGT）方面发展迅速。请问您如何评估目前新加坡在临床可及性、本地制造能力与监管框架三者之间的平衡？未来最关键的瓶颈是什么？ Francesca Lorraine Wei Inng Lim教授：我认为新加坡在细胞与基因治疗领域的发展机遇得天独厚。我们系统吸收了美国、欧洲乃至中国的先进经验，但必须承认当前全球细胞与基因治疗领域的技术主导力量仍集中在这些传统强国。基于此，我国临床团队已建立完善的国际化培训体系——多名临床医生被派往MD安德森癌症中心、纽约纪念斯隆凯特琳癌症中心、伦敦国王学院等全球顶尖CAR-T治疗中心进修，护理团队同样接受标准化培训，确保细胞治疗产品能够安全规范地应用于患者。在硬件设施层面，新加坡国家级GMP平台已具备充足产能，新建的ACTRIS设施作为大型多功能生产中心，可同步处理多种细胞治疗产品，这得益于政府前瞻性的政策支持。现行的双证体系（生产许可证+GMP证书）为产品质量提供了制度保障，基础设施层面已不存在实质性障碍。监管框架方面，正如我在本次演讲中所述，新加坡的法规体系正随着技术发展持续完善。我们已建立明确的指导文件，确保创新细胞与基因治疗产品的引进、转化及临床应用全过程符合质量安全要求。当前患者获取创新疗法的途径较以往更趋灵活，但未来技术升级带来的挑战不容忽视——例如诱导多能干细胞（iPSC）技术深化应用后，如何建立新型产品的质量控制标准和临床放行准则，将成为监管机构与临床医生共同面临的重大课题。特别需要关注的是，当这些前沿疗法应用于罹患侵袭性血液系统恶性肿瘤的危重患者时，必须严格评估其潜在风险。我们尚未完全掌握新型细胞治疗产品的长期副作用谱系，这要求临床团队必须保持高度谨慎，避免对患者造成额外伤害。此外，高昂的治疗成本仍是制约患者可及性的关键因素，若产品定价持续维持在数十万美元区间，即便具有救命价值，其临床推广仍将面临伦理困境。值得强调的是，这些挑战并非全新课题，而是我们在CAR-T疗法临床应用过程中已积累的实践经验。核心团队需持续整合既有知识体系，将应对CAR-T疗法的成熟经验有效迁移至其他创新疗法，这种技术迭代与知识传承的闭环机制，正是推动新加坡成为区域细胞治疗中心的关键驱动力。（上下滑动查看英文原文） Singapore has seen rapid growth in cell and gene therapy. How do you assess the balance today between clinical access, local GMP manufacturing capacity, and the regulatory framework? What do you see as the single biggest bottleneck over the next years? Pro.Francesca Lorraine Wei Inng Lim：Singapore is in a notably advantageous position in the field of cell and gene therapy. We have gained substantial insights from leading regions including the United States, Europe, and China, which are currently the major powerhouses in this domain. To enhance local expertise, several of our clinicians have been sent to specialized international centers with significant experience in CAR-T therapy, such as MD Anderson, Memorial Sloan Kettering in New York, and King’s College in the UK. Consequently, both our medical and nursing staff are well-trained to administer cell-based therapies safely and effectively. In addition, Singapore has established a robust national GMP facility, which now possesses considerable capacity for local manufacturing. Although newly established, ACTRIS is a large-scale facility capable of simultaneous production of multiple cell therapy products. This initiative, supported by the government, provides a fully licensed and GMP-certified infrastructure, thereby alleviating potential manufacturing constraints. Regarding regulatory frameworks, Singapore’s guidelines are continually evolving. Clear guidance documents are available to facilitate the safe and quality-assured translation of cell and gene therapies from bench to bedside. This regulatory maturation is critical for sustaining progress in the field. However, several challenges lie ahead. As technologies advance—for instance, with the use of induced pluripotent stem cells (iPSCs) and their subsequent genetic modification—questions arise concerning quality control, safety profiling, and appropriate release criteria for clinical application. These challenges extend beyond regulatory bodies to clinicians themselves, especially when treating critically ill patients with aggressive malignancies. The potential side effects of novel therapies must be thoroughly evaluated to avoid additional harm. Furthermore, the high cost of these treatments remains a significant barrier. With prices ranging into the hundreds of thousands of dollars, patient accessibility becomes a pressing concern even for life-saving interventions. It is important to recognize that these challenges are not entirely new; many have already been encountered with CAR-T therapy in Singapore. Therefore, a collaborative and proactive approach—leveraging existing knowledge and experience—is essential to address these bottlenecks and facilitate the application of current learnings to other emerging therapeutic avenues. PART.2 新加坡作为区域中心，有“hub-and-spoke”跨境合作的先例以扩大 CAR-T 可及性。请问在伦理审查、患者迁移与长期随访方面，您遇到过哪些实际挑战？对想采用类似模式的邻国或中心，您有哪些政策或资源配置上的建议？ Francesca Lorraine Wei Inng Lim教授：新加坡中央医院在移植项目中采用"中心-辐射"模式已有较长历史。我们曾为越南等地的白血病和淋巴瘤患者实施骨髓移植治疗，术后患者通常返回原籍国，由当地血液科医生继续管理。基于这一经验，我们在开展CAR-T治疗项目时构建了类似体系：海外患者（如印度、越南）可直接来我院就诊，或由其原籍国医师通过临床渠道与我们团队对接病例。但病例讨论仅是流程的首要环节，后续必须经多学科会诊（MDT）形成治疗共识，即由肿瘤专家、移植团队、细胞治疗组、重症医学科及感染科医师共同参与的联合诊疗会议，对病例进行公开评估，以决定是否接收该海外患者。尤为关键的是，转诊国需建立持续管理患者的能力，确保其返国后仍能获得规范治疗。现代通讯技术（如Zoom、Microsoft Teams）显著改善了医患沟通效率，相较以往依赖电子邮件可能造成的延迟，实时视频会议使联合门诊成为可能——我院医师与海外医生可同步查看患者情况，实现全流程无缝管理。对于参与临床试验的患者，其伦理审查流程已较为成熟。但若患者因无其他治疗选择而寻求创新疗法，则必须通过医院伦理委员会的严格审核，确保患者充分理解治疗风险、获益及伦理考量，保障创新挽救性治疗的安全实施。我们尤其注重避免患者跨境治疗后出现严重并发症甚至死亡的情况，这是医患双方均不愿见到的最差结局。通过整合既有经验与技术升级，我院正不断完善"中心-辐射"模式的支持体系，以实现细胞治疗的安全推广与规范应用。（上下滑动查看英文原文） Singapore has served as a regional hub with a “hub-and-spoke” model to expand CAR-T access. What practical challenges have you faced regarding ethics review, patient movement, and long-term follow-up? What policy or resource-allocation advice would you give centers or neighboring countries seeking to adopt a similar model? Pro.Francesca Lorraine Wei Inng Lim：The hub-and-spoke model has been an integral part of our transplant program at Singapore General Hospital for a considerable time. For instance, we have regularly managed patients from Vietnam seeking bone marrow transplantation for leukemias and lymphomas in Singapore, with subsequent follow-up care coordinated with their local hematologists upon return to their home country. Similarly, with the initiation of our CAR-T therapy program, we adopted an analogous framework. This allows patients to directly contact our center or be referred by their physicians from overseas, such as from India or Vietnam, for clinical discussion. However, such inquiries represent only the initial step. Each case must undergo formal review by our multidisciplinary tumor board, which includes disease specialists, transplant and cell therapy team members, intensivists, and infectious disease experts. This collaborative evaluation determines our capacity to provide care for international patients in Singapore. Of paramount importance is ensuring that referring centers can continue management after the patient returns home. Advances in telecommunication—such as Zoom and Microsoft Teams—have significantly improved coordination compared to earlier reliance on email, which often incurred delays. We now emphasize structured virtual joint clinics to enable real-time consultation between our team and overseas physicians, ensuring seamless continuity of care throughout the treatment process. For patients entering Singapore under clinical trials, ethical oversight is inherently addressed within trial protocols. However, those seeking experimental therapies outside of trials must obtain approval from our institutional ethics committee. This ensures full comprehension of the risks, benefits, and ethical implications involved in receiving innovative salvage therapies. Our utmost priority is to avoid adverse outcomes, such as clinical deterioration or death during their stay in Singapore, both for the well-being of the patients and in maintaining collaborative trust with international partners. This comprehensive and ethically grounded approach underpins our support of the hub-and-spoke model. PART.3 展望未来，您如何看待新加坡在“从临床试验到商业化，以及推动国产化细胞治疗产品”这条路上的角色？在科研、产业与政府三方协作上，您最希望看到哪些具体举措来加速安全且公平的患者受益？ Francesca Lorraine Wei Inng Lim教授：对于学术界医师而言，将自主研发产品推进至注册上市及市场推广阶段存在显著挑战，单凭学术力量难以完成全流程运作，产业合作伙伴的参与至关重要。行业伙伴不仅能够提供市场准入及商业化推广的核心支持，更可通过规模化生产能力提升治疗产品的全球可及性，使新加坡本土研发成果惠及更广泛患者群体。鉴于新加坡本土人口规模仅约六百万，开展超大型单中心临床试验存在现实限制，需采用多中心或跨国合作模式——以新加坡为核心基地，联合马来西亚、越南等邻国乃至中国开展协同研究，通过积累高质量多中心数据为产品注册提供依据，进而实现产品在亚太地区的战略布局。这一过程需构建学术界、产业界与监管机构的深度协作机制，辅以政策支持，方能形成从基础研究到临床应用的全链条创新转化体系。（上下滑动查看英文原文） Looking ahead, how do you envision Singapore’s role in moving cell therapies from trials to commercialization and in fostering domestically developed cell therapy products? In collaboration between academia, industry and government, what concrete measures would you most like to see to speed safe and equitable patient benefit? Pro.Francesca Lorraine Wei Inng Lim：For physicians in academia, navigating the path to registration, commercialization, and broad distribution of a novel product presents significant challenges. This process is highly complex and cannot be undertaken alone, necessitating strategic collaborations with industry partners. Such partnerships are critically important, as industry involvement provides essential support in marketing, market entry, and scaling production capabilities to deliver the therapy to patients not only in Singapore but also worldwide. Given Singapore’s relatively small population of just over six million, conducting large-scale clinical trials domestically is particularly difficult. A multi-center or regional approach—conducting trials in Singapore while also engaging neighboring countries such as Malaysia, Vietnam, or through collaborations with China—is often required. Generating robust clinical data through such international efforts enables subsequent regulatory filing and facilitates distribution across the Asia-Pacific region. Therefore, collaboration between academia, researchers, and industry, supported by clear regulatory frameworks and government backing, is essential to overcoming these barriers and advancing innovative therapies to market. （来源：《肿瘤瞭望–血液时讯》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

细胞疗法基因疗法临床申请免疫疗法

2025-08-26

·PRNewswire

Cerecin Joins NIHR HealthTech Research Centre in Brain Health as an Industry Partner

DENVER, Aug. 26, 2025 /PRNewswire/ -- Cerecin, a global biotech company focused on neurometabolism, is proud to announce its partnership with the NIHR HealthTech Research Centre (HRC) in Brain Health, joining a distinguished group of industry leaders including GE Healthcare, Novo Nordisk, Roche Diagnostics, and Camtech Innovations. Continue Reading The HRC, based at King's College London and the South London and Maudsley NHS Foundation Trust, is dedicated to advancing the diagnosis, care, and treatment of dementia through cutting-edge technologies. The Centre will leverage brain scanning, blood sampling, computerized testing, and digital tools to develop more effective and earlier methods of diagnosing dementia, aiming to reduce its societal impact. Led by Professor Dag Aarsland, Director of the Centre for Healthy Brain Ageing at the Institute of Psychiatry, Psychology and Neuroscience, and Professor Clive Ballard of the University of Exeter, the HRC brings together academic excellence and industry innovation to tackle one of the most pressing challenges in neuroscience. Commenting on the partnership, Dr. Charles Stacey, President & CEO of Cerecin, said: "We are excited to join the HRC as an industry partner. King's College London has a world-class reputation in neuroscience research, and we believe that close collaboration between academia and industry is essential to accelerate innovation and bring impactful solutions to market. We are honored to join other industry leaders in advancing the future of brain health." Dr. Richard Siow, Director of Ageing Research at King's (ARK) and Industry Lead for the NIHR HealthTech Research Centre in Brain Health, added: "We are pleased to welcome Cerecin as an industry partner. Cerecin is at the forefront of neurometabolism, a critical area of neuroscience research with the potential for significant impact to enhance healthy brain ageing. We look forward to working together to explore opportunities across Cerecin's pipeline and beyond." As Cerecin advances the ALTER AD study, its pivotal Phase 3 program in Alzheimer's disease dementia with lead compound, tricaprilin, the company is actively pursuing strategic partnerships to strengthen its leadership in the field. These collaborations will support the development of both its current pipeline and future innovations, both independently and in concert with other industry leaders. About Cerecin Cerecin is a US-based clinical-stage biotechnology company focused on developing drugs that target the metabolic basis of neurological diseases. Cerecin's development programs leverage its extensive experience in neurology drug development and lipid science. Cerecin is supported by multinational partners; Nestlé, Wilmar and IOI. By combining the deep expertise of its leadership team with a highly differentiated drug development program, Cerecin is becoming a global leader in neurology therapeutics. Cerecin's lead compound, tricaprilin, is currently in Phase 3, the ALTER AD study, for mild to moderate Alzheimer's disease dementia. Tricaprilin enhances ketone production by delivering medium-chain fatty acids directly to hepatic mitochondria, where they are rapidly metabolized to acetyl-CoA. This acetyl-CoA enters the ketogenesis pathway, producing ketone bodies such as β-hydroxybutyrate (BHB), which are transported to extrahepatic tissues, converted back to acetyl-CoA, and utilized in the TCA cycle to generate ATP. This mechanism bypasses impaired glucose metabolism and supports energy production in metabolically compromised cells. For more information, visit or follow us on LinkedIn. SOURCE Cerecin, Inc WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期

2025-07-22

·今日头条

最新研究！同卵双胞胎并非“基因复刻”，表观遗传改写“命运双生”

同卵双胞胎曾被视为“自然克隆体”，近期，科学家发现尽管共享完全相同的DNA序列，他们在表观遗传层面存在显著差异，导致基因表达、疾病易感性乃至人生轨迹的分歧。这一发现不仅颠覆传统认知，更为解析癌症、糖尿病等复杂疾病提供了全新模型。从“完美替身”到“差异个体”：表观遗传的隐形雕刻 1992年，英国遗传学家Tim Spector启动“双胞胎英国计划”（TwinsUK），追踪1.5万对同卵及异卵双胞胎。 2005年的一项里程碑式研究发现，同卵双胞胎的DNA甲基化和组蛋白修饰模式随年龄增长逐渐分化——年长双胞胎的表观遗传差异比年轻者高出30%，证明环境与生活方式持续重塑基因表达。 “双胞胎是研究‘先天与后天’的天然实验场，”伦敦国王学院表观基因组学研究员Jordana Bell解释，“他们的DNA如同一本未装订的书，表观遗传标记决定哪些章节被‘阅读’。” 犯罪现场的DNA困局：当双胞胎成为“完美嫌疑人” 2004年美国密歇根州一起抢劫案中，罪犯DNA与Jerome Cooper匹配，但其同卵双胞胎兄弟Tyrone同样在场。由于传统法医技术无法区分两人DNA，案件悬而未决。此类案例凸显表观遗传学的潜在价值：若能检测DNA甲基化差异，或可破解“双胞胎犯罪谜题”。 Bell透露，已有执法机构咨询通过表观遗传标记区分双胞胎的可能性，“但单一技术不足以定罪，需结合蛋白质组学等多维度数据”。疾病预警：表观遗传标记提前数年发出信号研究显示，表观遗传差异可预示疾病风险。Bell团队发现，在患乳腺癌的双胞胎中，肿瘤抑制基因BRCA1的启动子区出现超甲基化，且该修饰在肿瘤确诊前数年已存在。类似现象也见于白血病、2型糖尿病及肥胖症患者。 “这些标记可能是疾病的‘分子记忆’，”Bell指出，“但需进一步验证：是表观变化导致疾病，还是疾病引发修饰？这需要纵向追踪研究。” 未来方向：从实验室到个性化医疗科学家正整合基因组、表观基因组及蛋白质组数据，构建“多组学疾病图谱”。例如，澳大利亚双胞胎研究已发现，肥胖双胞胎的脂肪细胞中，PPARG基因的甲基化水平与代谢异常直接相关。 Bell强调：“表观遗传学不是万能钥匙，但它是理解复杂疾病的关键拼图。未来，我们可能通过调整表观标记来干预疾病，而非仅仅治疗症状。” 同卵双胞胎的差异证明，生命密码的解读远不止于DNA序列。随着表观遗传学与人工智能的融合，科学家正逐步揭开“基因如何被环境重塑”的奥秘，为精准医疗开辟新路径。正如Bell所言：“每个双胞胎都是一本活着的教科书，告诉我们——生命从未停止书写自己的故事。” 【关于投稿】转化医学网（360zhyx.com）是转化医学核心门户，旨在推动基础研究、临床诊疗和产业的发展，核心内容涵盖组学、检验、免疫、肿瘤、心血管、糖尿病等。如您有最新的研究内容发表，欢迎联系我们进行免费报道（公众号菜单栏-在线客服联系），我们的理念：内容创造价值，转化铸就未来！转化医学网（360zhyx.com）发布的文章旨在介绍前沿医学研究进展，不能作为治疗方案使用；如需获得健康指导，请至正规医院就诊。责任声明：本稿件如有错误之处，敬请联系转化医学网客服进行修改事宜！微信号：zhuanhuayixue 热门推荐活动点击免费报名 🕓 北京｜2025年9月19-20日 ▶ 第六届单细胞技术应用研讨会暨空间组学前沿研讨会点击对应文字查看详情

100 项与 King's College London 相关的药物交易

登录后查看更多信息

100 项与 King's College London 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年09月15日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

临床1期

临床2期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

IRL-201805 ( RANK x RANKL )	类风湿关节炎更多	临床2期
Rasolvir(King's College London)	类风湿关节炎更多	临床2期
LEU-001 ( EGFR )	头颈部肿瘤更多	临床2期
[11C]MK-8278 ( H3 receptor )	精神分裂症更多	临床1期
KCL-286 ( RARβ2 )	脊髓损伤更多	临床1期